DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Capmatinib
Capmatinib
Tabrecta (Capmatinib)
Incyte Corporation
First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations
Capmatinib) Tablets, for Oral Use Hepatotoxicity: Monitor Liver Function Tests
(CHMP) Agenda for the Meeting on 22-25 March 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion- Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Data from Incyte's Oncology Portfolio Accepted for Presentation at The
NCCN Guidelines for Central Nervous System Cancers Cancer V.1.2021 – Annual 10/23/2020
Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
Targeted Therapy for Lung Cancer (Faculty Presentations)
Westfield USHP Slides Handout
Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors And
New Frontiers in Therapy of Peripheral Nerve Sheath Tumors In
Targeted Therapy Inflammation
Recommendations of the SEC (Oncology &Haematology) Made in Its 92Nd Meeting Held on 03.12.2019 at CDSCO HQ New Delhi: Agenda
Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Effective: August 16, 2021
Potential Exploration of Recent FDA-Approved Anticancer Drugs Against Models of SARS-Cov-2’S Main Protease and Spike Glycoprotein: a Computational Study
Top View
MET Inhibitor, Capmatinib Overcomes Osimertinib Resistance Via
Non-Small Cell Lung Cancer
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
Informing Treatment Strategies Through a Comprehensive Approach
Specialty Pipeline MONTHLY UPDATE
Oncology Comprehensive Drug List Krogerspecialtypharmacy.Com
213591Orig1s000
MET Exon 14 Skipping Alterations in Non-Small Cell Lung Carcinoma—Current Understanding and Therapeutic Advances
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Oncology Agents Policy #: Rx.01.67
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
Optimizing Use of Biomarkers in Managing Metastatic Non−Small Cell Lung Cancer the Role of the Oncology Health Care Team Faculty Information
Fourth-Line Treatment Approved for Gastrointestinal Tumor
Novartis Data at ASCO and EHA Demonstrate Novel Approaches to Reimagining Medicine in Cancer and Serious Blood Disorders
Non-Small Cell Lung Cancer Targetable Mutations: Present and Future
List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
20200826 Patel Lung Cancer HANDOUT
SRC and PIM1 As Potential Co-Targets to Overcome Resistance in MET Deregulated Non-Small Cell Lung Cancer
Our Comprehensive Genomic Profiling Revolves Around Your Patient
WHO Drug Information Contents
Tyrosine Kinase Inhibitors - Oral
Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
New Prescription and OTC Medication Update
Drug Information Center Highlights of FDA Activities – 5/1/2020 – 5/31/2020
Company Overview
Stage Iii/Iv Braf/Nras Wild-Type Melanoma Nct# 02587650
Capmatinib (INC280)
New Drug Is a Triple Threat Against RET-Altered Cancer
Capmatinib (Tabrecta™) EOCCO POLICY
Pipeline Report
RFP: February 11, 2021
Oncology Orals Medications
213591Orig1s000
213591Orig1s000
Acquired Resistance of MET-Amplified Non-Small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant NSCLC
Tyrosine Kinase Receptors in Oncology
Targeted Therapy Inflammation/ Autoimmunity Immuno-Oncology